Pasar al contenido principal

Cristina Solé Marce

I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs.

Instituciones de las que forman parte

Investigador/a principal
Reumatología
Vall Hebron Institut de Recerca

Cristina Solé Marce

Instituciones de las que forman parte

Investigador/a principal
Reumatología
Vall Hebron Institut de Recerca

I am a Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute. Previously, I held a postdoctoral research position in the same unit, and during my PhD, I conducted research at the University of Durham (Durham, UK), Anacor Pharmaceuticals (California, USA), and Rovira i Virgili University (Tarragona, Catalonia). I hold a dual degree in Chemistry and Biochemistry, and during these studies, I also conducted research at the University of Reading (Reading, UK) and the University of the Balearic Islands (Mallorca, Spain). My research career has focused on autoimmune diseases, particularly on the pathogenesis of lupus and antiphospholipid syndrome, as well as the synthesis and mechanisms of action of biological drugs.

Since 2021, I am Senior-Junior Principal Investigator in the Rheumatology team at the Systemic Lupus Erythematosus Unit of the Vall Hebron Research Institute (VHIR). Previously, I spent six years as a postdoctoral researcher in the same unit. Since then, our focus has been on research aimed at improving patients' lives, whether through the identification of new biomarkers that inform us about their condition without the need for invasive techniques, or through the discovery of the effects of new drugs and/or the molecular pathways involved in the development of different clinical manifestations. In this regard, we have already published several papers in internationally recognized journals and have been invited to prestigious conferences (ACR, EULAR, etc.).

Before joining VHIR, I graduated with dual degrees in Chemistry and Biochemistry from Rovira i Virgili University, where I achieved the highest academic record in both programs. I then began my PhD, focusing on the enantioselective synthesis of drugs, while simultaneously completing a master’s degree in "Synthesis and Catalysis" at Rovira i Virgili University.

I have completed various research stays at national, European, and international levels. Specifically, I worked at the University of the Balearic Islands with Dr. Palou's team, researching the regulation of metabolism via ghrelin/leptin. I then conducted research at Reading University with Dr. Katja Strohfeldt, synthesizing anticancer drugs based on germanium. Additionally, I worked at Durham University with Dr. Andy Whiting, exploring new enantio- and diastereo-selective pathways for drug synthesis. Finally, before joining my current team, I worked at Anacor Pharmaceuticals in Palo Alto (California, USA), both in the chemical synthesis and biological departments.

Proyectos

RNA-seq en exosomas urinarios para detectar nuevos biomarcadores de progresión de la nefritis lúpica

IP: José Ordi Ros
Colaboradores: Cristina Solé Marce
Entidad financiadora: Instituto de Salud Carlos III
Financiación: 110715
Referencia: PI15/02117
Duración: 01/01/2016 - 31/12/2019

Autoimmunitat i Malaltia Trombòtica (GRC)

IP: Miguel Vilardell Tarres
Colaboradores: Carmen Pilar Simeón i Aznar, Roser Solans Laque, Segundo Bujan Rivas, Vicenç Fonollosa Pla, José Ordi Ros, Josefina Cortes Hernandez, Fernando Martínez Valle, Albert Selva O'Callaghan, Cristina Solé Marce
Entidad financiadora: Agència Gestió Ajuts Universitaris i de Recerca
Financiación:
Referencia: 2014 SGR 329
Duración: 01/01/2014 - 31/12/2016

Noticias relacionadas

Financiado por la Unión Europea, este proyecto coordinado por el Vall d’Hebron Instituto de Investigación (VHIR) busca nuevas combinaciones de medicamentos ya existentes para lograr terapias más efectivas.

La media para llegar al diagnóstico de una enfermedad minoritaria es de 5 años. Vall d'Hebron, el centro del Estado con más ensayos clínicos autorizados, se suma ahora a la nueva alianza europea ERDERA para coordinar y agilizar la investigación.

La Semana de la Ciencia se dirige a todos los públicos y tiene como objetivos hacer accesible la ciencia y la tecnología a la ciudadanía y fomentar las vocaciones científicas entre los más jóvenes.

Profesionales relacionados

Maria Eugenia Bustelo Almeida

Maria Eugenia Bustelo Almeida

Técnico de investigación
Cáncer y Enfermedades Hematológicas Infantiles
Leer más
Janet Illa Bernadí

Janet Illa Bernadí

Técnico de investigación
Neumología
Leer más
Daniel Acosta Eyzaguirre

Daniel Acosta Eyzaguirre

Investigador postdoctoral
Investigación Biomédica en Tumores del Aparato Digestivo
Leer más
Anna Fàbregas Fernández

Anna Fàbregas Fernández

Auxiliar de investigación
Investigación Biomédica en Ginecología
Leer más

Suscríbete a nuestros boletines y forma parte de la vida del Campus

Vall d'Hebron Barcelona Hospital Campus es un parque de referencia mundial donde la asistencia, la investigación, la docencia y la innovación se dan la mano.